MAY 06, 2016 1:46 PM PDT

Biomarker Predicts Childhood Cancer Relapse

WRITTEN BY: Xuan Pham
Lack of a protein indicates high risk of childhood cancer recurrence
Researchers say a protein biomarker could indicate whether a childhood cancer, neuroblastoma, will relapse. Absence of the marker, known as PML, was associated with tumor recurrence. The team says this piece of information could improve patient outcome, as therapies can be tailored according to a patient’s diagnostic result for the PML marker.
 
Neuroblastoma is a type of cancer that affects nerve cells in the sympathetic nervous system (PNS). This cancer is one of the most common forms of childhood cancer, affecting infants and young children. It is rarely found in children older than 10 years.
 
Children diagnosed with high-risk neuroblastoma, indicated by onset under 5 years of age and metastatic potential, are treated with intensive chemotherapy, surgery, radiation, and even bone marrow transplantation. In contrast, for low-risk neuroblastoma patients, doctors may opt to continuously monitor the tumor with or without surgical intervention. This method of “wait-and-see” has 90 percent prognosis rate for low-risk patients, but some deadly relapses can occur.
 
In testing neuroblastoma cell lines, the team at Brunel University London and University College London honed in on the PML protein, known formally as promyelocytic leukemia protein. They noted that PML is normally detected in the developing and adult PNS. However, PML expression was low or near absent in metastatic neuroblastoma tumors. The PML protein acts to suppress the development of blood vessels that feed the tumor cells, thus its absence is consistent with increased risk for tumor recurrence.
 
“In the low risk tumors, the absence of PML will be a very useful marker," said Arturo Sala, Professor at Brunel, and co-leader of the study. "What we can now say is that even some tumors classified as low risk, that would have previously gone untreated, if they show no expression of PML, they ought now to be classified as high risk.”
 
Indeed, the prognosis for low-risk neuroblastoma patients may even exceed 90 percent if these patients can be screened and treated promptly according to the presence or absence of PML. "It is an immediately applicable diagnostic tool," said Sala. "The cost is relatively small - it is just done by microscope inspection and could be used whenever a child is diagnosed by biopsy. If you save one child it is worthwhile."
 
In the next phase, the team has to validate their findings and confirm that PML levels can be predictive of neuroblastoma outcomes. Because the test would rely on a negative result – absence of PML – the team will need to find another biomarker to serve as a positive control. If successful, they will move to clinical trials to establish the effectiveness of this biomarker. 
 

Additional source: MNT
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 04, 2021
Cancer
Good News for Coffee Lovers: A New Study Finds Caffeine Does Not Impact Breast Cancer Risk
OCT 04, 2021
Good News for Coffee Lovers: A New Study Finds Caffeine Does Not Impact Breast Cancer Risk
Reports indicate that caffeine consumption in the United States is greatest in adults aged 50 – 64.  Coincide ...
OCT 14, 2021
Cancer
Mechanism of Resistance to Colorectal Cancer Treatment Uncovered
OCT 14, 2021
Mechanism of Resistance to Colorectal Cancer Treatment Uncovered
Colorectal cancer develops when a series of changes occur across multiple genes.  While researchers have paid signi ...
OCT 21, 2021
Cancer
Exercise: A Secret Weapon to Combat Prostate Cancer?
OCT 21, 2021
Exercise: A Secret Weapon to Combat Prostate Cancer?
Exercise oncology is an evolving science that considers the addition of physical activity regimens to the treatment ...
OCT 24, 2021
Microbiology
New Treatment Approach Uses Bacteria to Deliver Drugs to Cancer Cells
OCT 24, 2021
New Treatment Approach Uses Bacteria to Deliver Drugs to Cancer Cells
Bacteria can be found almost everywhere, and they can serve many beneficial purposes. Scientists are now using bacterial ...
NOV 04, 2021
Cancer
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
NOV 04, 2021
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
Despite the incremental success immune checkpoint inhibitors (ICI) have attributed to the cancer treatment landscape rec ...
NOV 22, 2021
Cancer
A New Treatment Option for Patients with Cancer in the Eye
NOV 22, 2021
A New Treatment Option for Patients with Cancer in the Eye
Uveal melanoma (UM) is a rare malignancy characterized by the formation of cancer cells in the tissues of the eye. UM be ...
Loading Comments...